Cleveland Williams, MD
General Practice · Washington, DCNPI 1417197435
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 82 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 20.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $477 and has fallen 67.3% since, to $156 in 2024.
Across 82 payments — averaging $17.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$294
- AstraZeneca$206
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$155
- Vanda Pharmaceuticals Inc.$151
- Gilead$101
- Indivior Inc.$72
- plus $467 from 15 others
What the payments were for
- Food & beverage$1,445100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 16 | $294 |
| AstraZeneca | 12 | $206 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 15 | $155 |
| Vanda Pharmaceuticals Inc. | 6 | $151 |
| Gilead | 5 | $101 |
| Indivior Inc. | 3 | $72 |
| Johnson & Johnson(2 entities) | 3 | $56 |
| GSK | 2 | $55 |
| Hikma Pharmaceuticals USA | 3 | $51 |
| Boehringer Ingelheim | 2 | $43 |
| Ironwood Pharmaceuticals, Inc | 3 | $43 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $34 |
| Bayer | 1 | $34 |
| Sunovion Pharmaceuticals Inc. | 2 | $30 |
| Hologic Sales And Service, LLC | 1 | $26 |
| E.r. Squibb & Sons, L.L.C. | 1 | $24 |
| Avion Pharmaceuticals | 1 | $18 |
| MDD US Operations, LLC | 1 | $16 |
| Novo Nordisk | 1 | $14 |
| Pfizer | 1 | $13 |
| Aytu Biopharma, Inc. | 1 | $11 |
How this compares
$1,445 in reported general payments places this provider in the 85th percentile of 272 general practice providers in District of Columbia.
See all general practice providers in District of Columbia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 355 | $192,591 |
| OzempicSemaglutide | 83 | $92,470 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 13 | $51,680 |
| MounjaroTirzepatide | 39 | $50,852 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 69 | $45,512 |
| EliquisApixaban | 48 | $27,674 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 53 | $26,957 |
| JardianceEmpagliflozin | 31 | $26,717 |
| TradjentaLinagliptin | 37 | $22,083 |
| SymbicortBudesonide/Formoterol Fumarate | 88 | $20,703 |
| Varenicline Tartrate | 61 | $18,326 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 28 | $17,950 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 880 | $15,326 |
| Megestrol Acetate | 187 | $14,418 |
| Diltiazem 24hr Er (La)Diltiazem Hcl | 210 | $14,364 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess | $294 | $192,591355 claims |
| Novo NordiskOzempic | $14 | $92,47083 claims |
| Boehringer IngelheimCombivent Respimat, Jardiance, Tradjenta, Spiriva Respimat | $43 | $81,596132 claims |
| GSKTrelegy Ellipta, Incruse Ellipta | $55 | $54,07193 claims |
| GileadBiktarvy | $101 | $51,68013 claims |
| AstraZenecaSymbicort, Breztri Aerosphere, Brilinta | $206 | $45,910130 claims |
| PfizerEliquis | $13 | $27,67448 claims |
| Johnson & JohnsonXarelto | $56 | $10,98619 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 272 general practice providers in District of Columbia.
Other general practice in Washington
- Brian GrayWashington$217K
- Fahad AshrafWashington$39K
- Shila YazdaniWashington$11K
- Roman MossWashington$11K
- John TsaknisWashington$10K
- Brian ChangWashington$8K
- Ileana EsparragueraWashington$8K
- Sheila SamaddarWashington$7K
- Sinclair DavisWashington$6K
- Christina MillsWashington$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.